Lund University Bioscience AB has decided to distribute its shares in Cantargia AB
Cantargia AB (”Cantargia”) announce that Lund University Bioscience AB (LU Bio) has had an extraordinary general meeting 31 January, 2018. It was decided that the company’s shares in Cantargia AB, will be distributed to its LU Bio’s shareholders. The distribution is planned to occur during week 6 2018. LU Bio has 4 056 828 shares in Cantargia AB, divided on 30 shareholders. Several of these are also existing shareholders in Cantargia. LU Bio’s largest owners are Stiftelsen Akademihemman (11,02 %), LU Holding AB (10,02%), Kudu AB (10,0%), LMK Forward AB (9,11%) and Östersjöstiftelsen (7,94%).
”LU Bio is a consortium of investors who has supported Cantargia, among others, from its foundation, during its early development until the position the company has today,” says Lars H.Bruzelius, chairman of the board in LU Bio and board member in Cantargia. ”This task has now been finalized in a successful way and it is with great pleasure the shares can now be distributed to our investors”.
“The support from LU Bio has been instrumental in the development of Cantargia. Moving forward, a direct ownership by its investors is of relevance for Cantargia”, says Göran Forsberg, CEO Cantargia. “We are grateful for LU Bio’s contribution. We look forward to continue the development of our assets for a positive clinical phase II outcome, with existing and new investors”.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
This constitutes information which Cantargia is required to publish under the EU’s Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the above contact person on 1 February 2018, at 08:30.
About Cantargia
Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing antibody-based treatments for life-threatening diseases. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein (IL1RAP) in leukemic stem cells. Subsequent research has also identified IL1RAP in many other forms of cancer. The company’s main project, the CAN04 antibody targeted at IL1RAP, is being studied in the CANFOUR clinical phase I/IIa study, where the primary focus is on non-small cell lung cancer and pancreatic cancer. CAN04 has two modes of action: it blocks the function of IL1RAP and stimulates the immune system to destroy tumour cells. Cantargia’s second project, currently in the research phase, is aimed at developing an IL1RAP-binding antibody that is optimised for treatment of autoimmune and inflammatory diseases.
Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.